drugset / Trial / NCT02228590

A Study to Examine APL-130277 in Patients With Parkinson's Disease

NCT02228590

Phase 2 Completed 20 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the efficacy, tolerability and safety of single treatments of APL-130277 in 16 patients with Parkinson's Disease (PD)

Timeline

Start
2014-08-31
Primary completion
2014-11-24
Completion
2014-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject APL-130277 Unknown Other

Indications